Know Cancer

or
forgot password

Randomized Phase I/II of Rapamycin Analog, RAD001, in Advanced Hepatocellular Carcinoma - With a Pharmacokinetic Study of RAD001


Phase 1/Phase 2
20 Years
75 Years
Open (Enrolling)
Both
Hepatocellular Carcinoma

Thank you

Trial Information

Randomized Phase I/II of Rapamycin Analog, RAD001, in Advanced Hepatocellular Carcinoma - With a Pharmacokinetic Study of RAD001


Objectives´╝Ü

1. Primary Objectives

- Phase I: To assess the maximal tolerated dose (MTD) of once daily and weekly oral
RAD001 in patients with advanced HCC of Child-Pugh's class A or B

- Phase II: To assess the disease control rate of advanced Child-Pugh's class A or B
HCC patients receiving the determined MTD of once daily and weekly oral RAD001 in
phase I

2. Secondary Objectives

- Phase I: To investigate the following items in the advanced HCC patients receiving
RAD001

1. Dose-limiting toxicity

2. Pharmacokinetics study

3. Pharmacogenetic study

4. Surrogate marker study on the PTEN, total and Phosphorylated forms of Akt of
tumor tissues

5. Disease control rate

- Phase II: To investigate the following items in the advanced HCC patients
receiving RAD001

1. Overall survival

2. Toxicity profile

3. Pharmacogenetic study

4. Surrogate marker study on the PTEN, total and Phosphorylated forms of Akt of
tumor tissues

Study Design: This study will be a randomized phase I study with dose escalation and
subsequently a phase II study of intent to treat, as well as pharmacokinetic,
pharmacogenetic and surrogate marker study of RAD001.

Sample Size: Upto 134 patients (Phase I: in cohort of 3-6 to test each dose level and a upto
48 patients to reach the expected MTD, 24 patients in each schedule of treatment arm; Phase
II: 18 patients of each schedule at the first stage and 25 patients of each schedule at the
second stage).

Study Medication: The RAD001 dose level of daily schedule will be escalated from 2.5, 5.0,
7.5 to 10 mg/day without splitting, with or without food. The RAD001 dose level of weekly
schedule will be escalated from 20, 30, 50 to 70 mg/week without splitting. The dose and
schedule of RAD001 in the phase II study will be dependent on the result of phase I study.
RAD001 will be supplied by Novartis Co.,

Study Conduct: Patients will be enrolled onto a sequence of receiving an oral dose of
RAD001. The schedule of RAD001 will be either once daily or once weekly. Throughout the
whole phase I and II study, an eligible patient will be randomized into either arm of daily
or weekly schedule. In the phase I part, each cohort of dose level will have 3 patients.
The dose of oral RAD001 will be initially fixed at 2.5 gm/day in daily schedule arm and at
20 mg/week in weekly schedule arm. One treatment course is defined as 4 weeks of RAD001
therapy. When no patient experiences dose-limiting toxicity (DLT) at certain level,
subsequent patients would be randomized to the next dose level. When 1 out of 3 patients
developed DLT, 3 additional patients would be treated with the same dose level. Three
patients will be further recruited to the next dose level when none of that 3 additional
patients experience DLT. No intra-individual dose-escalation will be performed. In the phase
II part, Simon's optimal two-stage approach will be used in both daily and weekly schedules.
If one responder is observed at the first stage of eighteen patients in either treatment
schedule, further twenty-five patients will be accrued.

Therapeutic Assessment´╝Ü

1. Efficacy assessment:

- Radiological response: To evaluate the disease control rate (complete response +
partial response + stable disease) by computed tomography after every 8 weeks of
therapy and according to RECIST guideline.

- Biological response

1. To evaluate the change of serum a-fetoprotein level.

2. To evaluate the change of plasma angiogenic factors levels.

2. Safety Assessment: Toxicity assessment:

- Evaluation of toxicity will be performed on patient-base.

- Clinical and laboratory toxicity/symptomatology will be graded according to NCI
common toxicity criteria (CTC) version 3.0.

- Abnormal liver functional tests are common in patients with HCC, only abnormal
elevation of ALT will be considered as indicator of hepatotoxicity.

3. Pharmacokinetic, Pharmacogenetic & Surrogate Marker Assessments

- Pharmacokinetic assessments:

1. Cmax: peak concentration

2. tmax: time to achieve peak concentration

3. Cmin: trough concentration

4. Cave: average concentration

5. AUCt: area under curve within a given time

6. t1/2: elimination half life

- Pharmacogenetic assessments:

1. Polymorphic CYP3A4

2. Polymorphic CYP3A5

3. Polymorphic P-glycoprotein

- Surrogate marker assessments:

1. PTEN

2. Total and Phosphorylated forms of Akt

Procedures:

1. Screening will be done within 2 weeks before starting treatment, and will include all
parameters listed below, (except for pharmacokinetics, AEs/concomitant medications, and
toxicity assessments) as well as informed consent, patient eligibility, medical
history, a pregnancy test (if indicated), EKG, and urinalysis.

2. During treatment:

- Physical examination (including vital sign measurements), height, weight, AEs, and
toxicity evaluation at the first day of each week during the initial 4 weeks,
biweekly at the subsequently 8 weeks and 4-weekly thereafter.

- Performance status will be assessed on the first day of each treatment course.

- Investigators/research nurses should monitor patients in each treatment course and
should instruct patients regarding the signs and symptoms of RAD001 toxicity as
described in the "Information for Patients" section of the RAD001 product
labeling.

- The laboratory tests, hemogram, clinical chemistry will be conducted weekly at the
first 4 weeks, biweekly at the subsequent 8 weeks and 4- weekly thereafter.

- Imaging studies for tumor response will be performed every 2 courses.

- Patient clinical and biological responses will be noted at the end of the study.

Statistical Analysis: No formal inferential statistical analyses will be performed. Data
will be summarized using descriptive statistics (number of patients, mean, median, standard
deviation, minimum, and maximum) for continuous variables and using frequency and percentage
for discrete variables. For the safety analyses, data will be presented for all patients.
An accounting of the study patients by disposition will be tabulated. Demographic data
(e.g., age, gender), medical history, cancer history, and other baseline characteristics
will be summarized.

1. Safety Evaluation: The general safety and tolerability of RAD001 will be assessed using
the following safety endpoints: AEs, routine clinical laboratory evaluations (hemogram,
serum chemistry, and urinalysis), physical examination, concomitant medications, and
Eastern Cooperative Oncology Group (ECOG) performance status. The grade of AEs at the
time of rescue as determined from the NCI-CTC version 3.0.

2. Pharmacokinetic Analysis: Pharmacokinetic parameters will be determined from plasma
drug and metabolite concentration curves using non- compartmental approaches. Mean (SD)
plasma drug concentration values will be summarized and plotted for each dose group.
All parameters described will be summarized with means and standard deviations. The
concentration in plasma determined at each sampling time point will be furnished on the
original scale for each subject participating in the study. The pharmacokinetic
parameters Cmax, Cmin, Cave, and AUC will be analyzed on the logarithmic scale of
measurement. The parameters of elimination half- life and tmax will be analyzed on the
original scale.

3. Efficacy Analysis: The efficacious parameters will be determined by mean of disease
control rate and median of time to tumor progression (TTP) and overall survival (OS)
using Kaplan-Meier method. The efficacious parameters will be added with 95% confidence
interval. All calculations will be based on the intent-to-treat principle.


Inclusion Criteria:



- Patients with measurable, metastatic or locally advanced HCC that are not feasible to
have or have failed to prior local therapy (including surgical resection,
transarterial chemoembolization and/or alcohol injection) are eligible.

- The diagnosis of HCC should be established either by cyto/histology; or, by
characteristic imaging studies (have to including angiography) plus serum level of
AFP equal to or more than 400 ng/mL in patients with cirrhosis of the liver and/or
chronic viral hepatitis B or C infection.

- Patients must be equal to or more than 20 years of age and equal or less than 75
years of age.

- Patients must have a performance status of ECOG score equal to or less than 2.

- Patients must fulfill all of the following criteria: Child-Pugh's Score equal to or
less than 9; serum total bilirubin level is equal to or less than 2.0 mg/dL; serum
ALT level (GPT) equal to or less than 3.0 x upper normal limit; platelet are equal to
or more than 50,000 / uL; WBC are equal to or more than 3,000 / uL.

- Serum creatinine equal to or less than 2.0 x upper normal limit.

- Life expectancy equal to or more than 12 weeks.

- Signed informed consent.

- Sexually active patients, in conjunction with their partner, must practice birth
control during, and for 2 months after therapy.

- Female patients at child-bearing age must have negative pregnancy test.

- No known HIV infection.

Exclusion Criteria:

- Patients with diseases which require concurrent usage of glucocorticosteroid or
immunosuppressant agent(s) are not eligible.

- Patients with concomitant active secondary malignancies, except for surgically cured
carcinoma in situ of the cervix and basal or adequately treated squamous cell
carcinoma of the skin, or disease-free of malignancies < 3 years before the study,
are not eligible.

- Patients with active infection are not eligible.

- Patients who received other rapamycin analogs before are not eligible.

- Patients with severe cardiopulmonary diseases (including history of stable,
effort-induced or unstable angina pectoris or myocardiac infarction) and other
systemic diseases under poor control are not eligible.

- Patients with history of psychiatric disorder are not eligible.

- Patients with brain metastases are not eligible.

- Patients who received surgery, radiotherapy except to bone, chemotherapy,
immunotherapy, or other investigational drug within 4 weeks before initiating study
are not eligible.

- Patients who are pregnant, breast-feeding or not using appropriate birth control
during the course of the study are not eligible.

- Patients with significant concomitant disease that will be aggravated by the
investigational drug are not eligible.

- Patients on active treatment with inhibitors or inducers of P-glycoprotein, CYP3A4
and CYP3A5 are not eligible; a minimal of 2 weeks wash-out period will be required
after stop such medications.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum tolerated dose in Phase I

Outcome Time Frame:

June-2008

Safety Issue:

Yes

Principal Investigator

Li-Tzong Chen, M.D., Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Institute of Cancer Research, National Health Research Institutes, Taiwan

Authority:

Taiwan: Department of Health

Study ID:

CRAD001C2453

NCT ID:

NCT00390195

Start Date:

October 2006

Completion Date:

June 2011

Related Keywords:

  • Hepatocellular Carcinoma
  • Hepatocellular carcinoma
  • RAD001
  • Rapamycin
  • Randomize
  • Phase I
  • Phase II
  • Pharmacokinetics
  • Carcinoma
  • Carcinoma, Hepatocellular

Name

Location